文献速递胸部肿瘤消化系统肿瘤

雷莫西尤单抗六项随机安慰剂对照试验个体患者安全性Meta分析

Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab.
PubMed 文献 · Ann Oncol · 2017-01-01

该个体患者Meta分析纳入六项全球随机双盲安慰剂对照III期试验的4996例经治患者(雷莫西尤单抗组2748例,安慰剂对照组2248例),评估血管内皮生长因子通路抑制相关不良事件。结果显示动脉血栓栓塞事件、静脉血栓栓塞事件、高级别出血及高级别消化道出血未见明确风险增加,但高血压、蛋白尿、低级别出血、消化道穿孔、输注相关反应及伤口愈合并发症在雷莫西尤单抗组发生率更高。

要点

  • 动脉血栓栓塞事件全级别RR 0.8(95%CI 0.5-1.3),高级别RR 0.9(95%CI 0.5-1.7),未见明确风险增加。
  • 静脉血栓栓塞事件全级别RR 0.7(95%CI 0.5-1.1),高级别RR 0.7(95%CI 0.4-1.2),未见明确风险增加。
  • 高血压、蛋白尿、低级别出血、消化道穿孔、输注相关反应及伤口愈合并发症在雷莫西尤单抗组发生率更高。

核心结论

  • 雷莫西尤单抗在动脉血栓栓塞事件、静脉血栓栓塞事件、高级别出血或高级别消化道出血方面可能区别于其他抗血管生成药物,本Meta分析未显示这些不良事件风险明确增加。
  • 雷莫西尤单抗在特定不良事件发生风险方面与其他血管生成抑制剂一致。

研究设计与样本

  • 对六项已完成的全球随机双盲安慰剂对照III期试验进行个体患者Meta分析,共纳入4996例经治患者,雷莫西尤单抗组2748例,安慰剂对照组2248例。
  • 采用固定效应或混合效应模型计算全级别和高级别不良事件的相对风险(RR)及95%置信区间(CI),不良事件为可能与血管内皮生长因子通路抑制相关者。
  • 因六项注册标准试验均为安慰剂对照,尚可计算需伤害人数。

主要发现

  • 动脉血栓栓塞事件全级别RR 0.8(95%CI 0.5-1.3),高级别(≥3级)RR 0.9(95%CI 0.5-1.7)。
  • 静脉血栓栓塞事件全级别RR 0.7(95%CI 0.5-1.1),高级别RR 0.7(95%CI 0.4-1.2)。
  • 高级别出血RR 1.1(95%CI 0.8-1.5),高级别消化道出血RR 1.1(95%CI 0.7-1.7)。
  • 与安慰剂对照组相比,雷莫西尤单抗组高血压、蛋白尿、低级别(1-2级)出血、消化道穿孔、输注相关反应及伤口愈合并发症发生率更高。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Ramucirumab, the human immunoglobulin G1 monoclonal antibody receptor antagonist of vascular endothelial growth factor receptor 2, has been approved for treating gastric/gastroesophageal junction, non-small-cell lung, and metastatic colorectal cancers. With the completion of six global, randomized, double-blind, placebo-controlled, phase III trials across multiple tumor types, an opportunity now exists to further establish the safety parameters of ramucirumab across a large patient population. MATERIALS AND METHODS: An individual patient meta-analysis across the six completed phase III trials was conducted and the relative risk (RR) and associated 95% confidence intervals (CIs) were derived using fixed-effects or mixed-effects models for all-grade and high-grade adverse events (AEs) possibly related to vascular endothelial growth factor pathway inhibition. The number needed to harm was also calculable due to the placebo-controlled nature of all six registration standard trials. RESULTS: A total of 4996 treated patients (N = 2748 in the ramucirumab arm and N = 2248 in the control, placebo arm) were included in this meta-analysis. Arterial thromboembolic events [ATE; all-grade, RR: 0.8, 95% CI 0.5-1.3; high-grade (grade ≥3), RR: 0.9, 95% CI 0.5-1.7], venous thromboembolic events (VTE; all-grade, RR: 0.7, 95% CI 0.5-1.1; high-grade, RR: 0.7, 95% CI 0.4-1.2), high-grade bleeding (RR: 1.1, 95% CI 0.8-1.5), and high-grade gastrointestinal (GI) bleeding (RR: 1.1, 95% CI 0.7-1.7) did not demonstrate a definite increased risk with ramucirumab. A higher percentage of hypertension, proteinuria, low-grade (grade 1-2) bleeding, GI perforation, infusion-related reaction, and wound-healing complications were observed in the ramucirumab arm compared with the control arm. CONCLUSIONS: Ramucirumab may be distinct among antiangiogenic agents in terms of ATE, VTE, high-grade bleeding, or high-grade GI bleeding by showing no clear evidence for an increased risk of these AEs in this meta-analysis of a large and diverse patient population. Ramucirumab is consistent with other angiogenic inhibitors in the risk of developing certain AEs. Clinical Trial Numbers: NCT00917384 (REGARD), NCT01170663 (RAINBOW), NCT01168973 (REVEL), NCT01183780 (RAISE), NCT01140347 (REACH), and NCT00703326 (ROSE).

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Arnold D, Fuchs CS, Tabernero J, et al. Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab. Ann Oncol. 2017. PMID: 28950290. doi:10.1093/annonc/mdx514

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。